An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
NACompletedINTERVENTIONAL
Enrollment
8
Participants
Timeline
Start Date
October 31, 2007
Primary Completion Date
October 31, 2013
Study Completion Date
October 31, 2013
Conditions
Leukemia, Myeloid, Chronic
Interventions
DRUG
Glivec®/Gleevec®
Chemotherapy
All Listed Sponsors
lead
King Faisal Specialist Hospital & Research Center
OTHER
NCT00538109 - An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase | Biotech Hunter | Biotech Hunter